Cargando…

Reflecting on 20 years of breast cancer modeling in CISNET: Recommendations for future cancer systems modeling efforts

Since 2000, the National Cancer Institute’s Cancer Intervention and Surveillance Modeling Network (CISNET) modeling teams have developed and applied microsimulation and statistical models of breast cancer. Here, we illustrate the use of collaborative breast cancer multilevel systems modeling in CISN...

Descripción completa

Detalles Bibliográficos
Autores principales:	Trentham-Dietz, Amy, Alagoz, Oguzhan, Chapman, Christina, Huang, Xuelin, Jayasekera, Jinani, van Ravesteyn, Nicolien T., Lee, Sandra J., Schechter, Clyde B., Yeh, Jennifer M., Plevritis, Sylvia K., Mandelblatt, Jeanne S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8211268/ https://www.ncbi.nlm.nih.gov/pubmed/34138842 http://dx.doi.org/10.1371/journal.pcbi.1009020

Ejemplares similares

Simulation modeling of breast cancer endocrine therapy duration by patient and tumor characteristics
por: Chandler, Young, et al.
Publicado: (2021)

Simulation Modeling to Extend Clinical Trials of Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Early Breast Cancer
por: Jayasekera, Jinani, et al.
Publicado: (2019)

Which Strategies Reduce Breast Cancer Mortality Most?: Collaborative Modeling of Optimal Screening, Treatment, and Obesity Prevention
por: Mandelblatt, Jeanne, et al.
Publicado: (2013)

Trade-Offs Between Harms and Benefits of Different Breast Cancer Screening Intervals Among Low-Risk Women
por: van Ravesteyn, Nicolien T, et al.
Publicado: (2021)

Emulator-based Bayesian calibration of the CISNET colorectal cancer models
por: Pineda-Antunez, Carlos, et al.
Publicado: (2023)

Collaborative modeling of the impact of obesity on race-specific breast cancer incidence and mortality
por: Chang, Yaojen, et al.
Publicado: (2012)

Personalizing Breast Cancer Screening Based on Polygenic Risk and Family History
por: van den Broek, Jeroen J, et al.
Publicado: (2020)

Development and Validation of a Simulation Model–Based Clinical Decision Tool: Identifying Patients Where 21-Gene Recurrence Score Testing May Change Decisions
por: Jayasekera, Jinani, et al.
Publicado: (2021)

Reassessing the Benefits and Harms of Risk-Reducing Medication Considering the Persistent Risk of Breast Cancer Mortality in Estrogen Receptor–Positive Breast Cancer
por: Jayasekera, Jinani, et al.
Publicado: (2023)

Impact of the COVID-19 Pandemic on Breast Cancer Mortality in the US: Estimates From Collaborative Simulation Modeling
por: Alagoz, Oguzhan, et al.
Publicado: (2021)

Using Collaborative Simulation Modeling to Develop a Web-Based Tool to Support Policy-Level Decision Making About Breast Cancer Screening Initiation Age
por: Burnside, Elizabeth S., et al.
Publicado: (2017)

Cost-Effectiveness of a Telephone-Based Smoking Cessation Randomized Trial in the Lung Cancer Screening Setting
por: Cao, Pianpian, et al.
Publicado: (2022)

Estimated US Cancer Deaths Prevented With Increased Use of Lung, Colorectal, Breast, and Cervical Cancer Screening
por: Knudsen, Amy B., et al.
Publicado: (2023)

Breast cancer risk for women with diabetes and the impact of metformin: A meta‐analysis
por: Lu, Yifan, et al.
Publicado: (2022)

Effect of Personalized Breast Cancer Risk Tool on Chemoprevention and Breast Imaging: ENGAGED-2 Trial
por: Wernli, Karen J, et al.
Publicado: (2021)

Epidemiological Determinants of Advanced Prostate Cancer in Elderly Men in the United States
por: Jayasekera, Jinani, et al.
Publicado: (2019)

Change in Survival in Metastatic Breast Cancer with Treatment Advances: Meta-Analysis and Systematic Review
por: Caswell-Jin, Jennifer L, et al.
Publicado: (2018)

A scoping review of interactive and personalized web-based clinical tools to support treatment decision making in breast cancer
por: Zhao, Amy, et al.
Publicado: (2021)

The Early Detection of Breast Cancer Using Liquid Biopsies: Model Estimates of the Benefits, Harms, and Costs
por: van der Poort, Esmée K. J., et al.
Publicado: (2022)

Overcoming barriers: Modelling the effect of potential future changes of organized breast cancer screening in Italy
por: Zielonke, Nadine, et al.
Publicado: (2023)

An ecological approach to monitor geographic disparities in cancer outcomes
por: Jayasekera, Jinani, et al.
Publicado: (2019)

Using Protection Motivation Theory to Predict Intentions for Breast Cancer Risk Management: Intervention Mechanisms from a Randomized Controlled Trial
por: Conley, Claire C., et al.
Publicado: (2021)

Evidence-based sizing of non-inferiority trials using decision models
por: Lansdorp-Vogelaar, Iris, et al.
Publicado: (2019)

Learning from and Leveraging Multi-Level Changes in Responses to the COVID 19 Pandemic to Facilitate Breast Cancer Prevention Efforts
por: Bowen, Deborah J., et al.
Publicado: (2021)

Extending Age Ranges in Breast Cancer Screening in Four European Countries: Model Estimations of Harm-to-Benefit Ratios
por: Zielonke, Nadine, et al.
Publicado: (2021)

Evaluation of health benefits and harms of the breast cancer screening programme in the Basque Country using discrete event simulation
por: Arrospide, Arantzazu, et al.
Publicado: (2015)

Finding the optimal mammography screening strategy: A cost‐effectiveness analysis of 920 modelled strategies
por: Kregting, Lindy M., et al.
Publicado: (2022)

Reply to: Comments on “Finding the optimal mammography screening strategy: A cost‐effectiveness analysis of 920 modeled strategies”
por: Kregting, Lindy M., et al.
Publicado: (2022)

Economic evaluation of the breast cancer screening programme in the Basque Country: retrospective cost-effectiveness and budget impact analysis
por: Arrospide, Arantzazu, et al.
Publicado: (2016)

A comparison between the effort-reward imbalance and demand control models
por: Ostry, Aleck S, et al.
Publicado: (2003)

An Example of Breast Cancer Regression on Imaging
por: Burnside, Elizabeth S., et al.
Publicado: (2015)

Outcomes and quality of life following breast cancer treatment in older women: When, why, how much, and what do women want?
por: Mandelblatt, Jeanne, et al.
Publicado: (2003)

Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk
por: Newcomb, P A, et al.
Publicado: (2010)

Sparse discriminative latent characteristics for predicting cancer drug sensitivity from genomic features
por: Knowles, David A., et al.
Publicado: (2019)

Molecular subtyping for clinically defined breast cancer subgroups
por: Zhao, Xi, et al.
Publicado: (2015)

CCAST: A Model-Based Gating Strategy to Isolate Homogeneous Subpopulations in a Heterogeneous Population of Single Cells
por: Anchang, Benedict, et al.
Publicado: (2014)

Validating agent-based simulation model of hospital-associated Clostridioides difficile infection using primary hospital data
por: Scaria, Elizabeth, et al.
Publicado: (2023)

Effects of cancer screening restart strategies after COVID-19 disruption
por: Kregting, Lindy M., et al.
Publicado: (2021)

A new perspective on breast cancer diagnostic guidelines to reduce overdiagnosis
por: Tunç, Sait, et al.
Publicado: (2022)

Correction: Effects of cancer screening restart strategies after COVID-19 disruption
por: Kregting, Lindy M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lp454iei7kvor235i738h1g5pp